It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The first vaccine against malaria is likely to be distributed in Africa from 2015 after the “milestone moment” of the continent’s largest final-stage drug trial, scientists have told The Times.
A meeting of 1,500 specialists in infectious disease will be told tomorrow that more than 5,500 children have been given the RTS,S vaccine, made by GlaxoSmithKline (GSK), the British pharmaceutical company, as part of the trial. Vaccine developers will tell the conference that the phase three trial is under way in seven countries around Africa, marking a major step in bringing the drug to licence.
Malaria is a parasitic disease that infects about 250 million people every year, resulting in almost a million deaths. It is caused by the Plasmodium parasite, which is passed to humans by infected mosquitoes when they bite. The disease can damage the nervous system, kidneys and liver, and severe cases can quickly lead to death.